-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules
.
.
in:
Xuanqijian bone tablets, the holder of the drug marketing license is Hunan Nanfangsheng Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
Qizhi Yishen Capsules, the drug marketing license holder is Shandong Phoenix Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
Kunxinning granules, the drug marketing license holder is Tasly Pharmaceutical Group Co.
, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
The above three innovative Chinese medicines are all developed based on the clinical experience of traditional Chinese medicine.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
In recent years, the State Drug Administration has fully implemented the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine ", followed the law of development of traditional Chinese medicine, inherited the essence, maintained integrity and innovation, continued to promote the reform of the review and approval mechanism of traditional Chinese medicine, and established and improved in line with the characteristics of traditional Chinese medicine.
The registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
The registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
The newly revised " Administrative Measures for Drug Registration ", "Classification of Chinese Medicine Registration and Requirements for Application Materials" and other regulations and related technical guidelines have been issued and implemented successively, fully respecting the law of the development of Chinese medicine, encouraging inheritance and innovation of Chinese medicine, and maximizing stimulation And released the vitality and potential of Chinese medicine innovation
.
.
As of 2021, the State Food and Drug Administration has approved 6 new Chinese medicines for the market on the basis of emergency approval of Qingfei Paidu Granules, Huashibaidu Granules, and Xuanfeibaidu Granules, becoming the most approved new Chinese medicines in the past 5 years.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules
.
.
in:
Xuanqijian bone tablets, the holder of the drug marketing license is Hunan Nanfangsheng Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
Qizhi Yishen Capsules, the drug marketing license holder is Shandong Phoenix Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
Kunxinning granules, the drug marketing license holder is Tasly Pharmaceutical Group Co.
, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
The above three innovative Chinese medicines are all developed based on the clinical experience of traditional Chinese medicine.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
In recent years, the State Drug Administration has fully implemented the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine ", followed the law of development of traditional Chinese medicine, inherited the essence, maintained integrity and innovation, continued to promote the reform of the review and approval mechanism of traditional Chinese medicine, and established and improved in line with the characteristics of traditional Chinese medicine.
The registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
The registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
The newly revised " Administrative Measures for Drug Registration ", "Classification of Chinese Medicine Registration and Requirements for Application Materials" and other regulations and related technical guidelines have been issued and implemented successively, fully respecting the law of the development of Chinese medicine, encouraging inheritance and innovation of Chinese medicine, and maximizing stimulation And released the vitality and potential of Chinese medicine innovation
.
.
As of 2021, the State Food and Drug Administration has approved 6 new Chinese medicines for the market on the basis of emergency approval of Qingfei Paidu Granules, Huashibaidu Granules, and Xuanfeibaidu Granules, becoming the most approved new Chinese medicines in the past 5 years.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules
.
.
in:
in: Xuanqijian bone tablets, the holder of the drug marketing license is Hunan Nanfangsheng Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
Medicines Medicines Medicines Chinese Medicine Chinese Medicine Chinese Medicine, Ltd.
, and its clinical trial research results show that it can be used for the treatment of mild to moderate knee osteoarthritis in traditional Chinese medicine
.
Qizhi Yishen Capsules, the drug marketing license holder is Shandong Phoenix Pharmaceutical Co.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
, Ltd.
, and its clinical trial research results show that it can be used for the treatment of early diabetic nephropathy with deficiency of both qi and yin
.
Kunxinning granules, the drug marketing license holder is Tasly Pharmaceutical Group Co.
, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
Medicine Medicine Medicine, Ltd.
, and its clinical trial research results have shown that it can be used for the treatment of female menopausal syndrome in TCM differentiation of kidney yin and yang deficiency
.
The above three innovative Chinese medicines are all developed based on the clinical experience of traditional Chinese medicine.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
Through randomized, double-blind, placebo parallel controlled, multi-center clinical trials, evidence of safety and efficacy has been obtained.
After approval, they will be clinically relevant diseases.
Of patients provide new treatment options
.
In recent years, the State Drug Administration has fully implemented the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine ", followed the law of development of traditional Chinese medicine, inherited the essence, maintained integrity and innovation, continued to promote the reform of the review and approval mechanism of traditional Chinese medicine, and established and improved in line with the characteristics of traditional Chinese medicine.
The registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
Chinese Medicine Chinese Medicine Chinese MedicineThe registration management system and technical evaluation system of the company are guided by clinical value to accelerate the development of new Chinese medicines
.
The newly revised " Administrative Measures for Drug Registration ", "Classification of Chinese Medicine Registration and Requirements for Application Materials" and other regulations and related technical guidelines have been issued and implemented successively, fully respecting the law of the development of Chinese medicine, encouraging inheritance and innovation of Chinese medicine, and maximizing stimulation And released the vitality and potential of Chinese medicine innovation
.
Drug Registration Drug Registration Drug Registration.
As of 2021, the State Food and Drug Administration has approved 6 new Chinese medicines for the market on the basis of emergency approval of Qingfei Paidu Granules, Huashibaidu Granules, and Xuanfeibaidu Granules, becoming the most approved new Chinese medicines in the past 5 years.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
In the past year, the reform of the Chinese medicine review and approval system has begun to show results
.
